Herein, we report a patient with stage IV NSCLC that harbored a novel <i>TPR-ROS1</i> fusion, which demonstrated a rapid but short partial response to first line crizotinib and primary resistance to subsequent ceritinib. Here, ROS1 is linked to non-small cell lung carcinoma.